Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH

Sponsor
Istanbul University - Cerrahpasa
Study ID
NCT07667673
Status
Recruiting
Apply to this trial

Conditions

  • Pulmonary Arterial Hypertension
  • Pulmonary Hypertension
  • Right Ventricular Function

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.

Key Dates

First listed
Jun 25, 2026
Start date
May 11, 2026
Status verified
Jun 2026
Primary completion
Feb 28, 2027
Completion
May 31, 2027

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Patients with Group 1 Pulmonary Arterial Hypertension
    Participants are adult patients with established Group 1 pulmonary arterial hypertension (PAH) undergoing follow-up at a specialized pulmonary hypertension center.

Primary Outcome Measure

Risk reclassification rate after incorporation of multimodality imaging-derived RV characteristics into established non-invasive PAH risk models [ Time Frame: Baseline and 6-month follow-up ]

Central Contacts

Related Studies